-
1 .
Anti-C5a antibody (vilobelimab) therapy for critically ill, invasively mechanically ventilated patients with COVID-19 (PANAMO): a multicentre, double-blind, randomised, placebo-controlled, phase 3 trial
- 저자
- by Alexander P J Vlaar; Martin Witzenrath; Pieter van Paassen; Leo M A Heunks; Bruno Mourvillier, et al.
- 소스
- The Lancet Respiratory medicine, 10(12), 1137-1146. ELSEVIER SCI LTD
Lancet respiratory medicine, 10(12), 1137-1146. Elsevier Limited
Lancet Respiratory Medicine, 10, 12, pp. 1137-1146
The lancet respiratory medicine
PANAMO study group 2022, ' Anti-C5a antibody (vilobelimab) therapy for critically ill, invasively mechanically ventilated patients with COVID-19 (PANAMO) : a multicentre, double-blind, randomised, placebo-controlled, phase 3 trial ', Lancet respiratory medicine, vol. 10, no. 12, pp. 1137-1146 . https://doi.org/10.1016/S2213-2600(22)00297-1
lancet. Respiratory medicine, 10(12), 1137-1146. Elsevier Limited
Lancet Respiratory Medicine, 10, 1137-1146